TGFB1 and pancreatic neoplasm: Pairing modulators of TGF-β signaling pathways with conventional systemic treatments such as chemotherapy and other immune modulators such as PD-1 inhibitors will address the mechanisms of resistance that have contributed to the poor outcomes of pancreatic cancer and allow for a more comprehensive treatment regimen.